Please assess the completion status of the following clinical trial:

Trial Title: Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients~* Patients diagnosed with insomnia disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)~* Patients who scored 15 or higher on the Insomnia Severity Index (ISI) at Visit 1~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Patients with a history of any of the following diseases according to the DSM-5 criteria:~  1. Hypersomnolence disorder~ 2. Narcolepsy~ 3. Breathing-related sleep disorders~ 4. Circadian rhythm sleep-wake disorder~ 5. Parasomnias~ 6. Restless legs syndrome~ 7. Substance/medication-induced sleep disorder~* Patients complicated with organic brain disease (including neurodegenerative disease, cerebrovascular disorder), and/or epilepsy~* Patients with a history of poorly controlled diabetes mellitus (HbA1c \>8%)~* Patients with difficulty in sleeping due to medical problems such as pain, pruritus, heart disease, nocturia (\>3 times per night), bronchial asthma, reflux oesophagitis, endocrine disease, hot flush, and periodic limb movement disorder~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
- 10 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
- 30 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
- Placebo (Type: PLACEBO_COMPARATOR): Period in which participants received single placebo prior to bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).